A Review of Systemic Biologics and Local Immunosuppressive Medications in Uveitis


Uveitis is one of the most common causes of vision loss and blindness worldwide. Local and/or systemic immunosuppression is often required to treat ocular inflammation in noninfectious uveitis. An understanding of safety and efficacy of these medications is required to individualize treatment to each patient to ensure compliance and achieve the best outcome. In this article, we reviewed the effectiveness of systemic biologic response modifiers and local treatments commonly used in the management of patients with noninfectious uveitis.


Corticosteroids, Immunosuppression, Uveitis

1. You C, Sahawneh HF, Ma L, Kubaisi B, Schmidt A, Foster CS. A review and update on orphan drugs for the treatment of noninfectious uveitis. Clin Ophthalmol 2017;11:257–265.

2. Durnian JM, Stewart RM, Tatham R, Batterbury M, Kaye SB. Cyclosporin-A associated malignancy. Clin Ophthalmol 2007;1:421–430.

3. O’Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006;25:1186–1191.

4. Kempen JH, Daniel E, Dunn JP, Foster CS, Gangaputra S, Hanish A, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ 2009;339:b2480.

5. Leal I, Rodrigues FB, Sousa DC, Duarte GS, Romão VC, Marques-Neves C, et al. Anti-TNF drugs for chronic uveitis in adults—a systematic review and meta-analysis of randomized controlled trials. Front Med 2019;6:104.

6. Aziz M, Fatima R. Infliximab [Internet]. Treasure Island, FL: StatPearls Publishing; 2022 [updated 2021 Jul 25]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500021/

7. van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531–1534.

8. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999;53:457–465.

9. Almoallim H, Al-Ghamdi Y, Almaghrabi H, Alyasi O. Anti-tumor necrosis factor-α induced systemic lupus erythematosus. Open Rheumatol J 2012;6:315–319.

10. Kruh JN, Yang P, Suelves AM, Foster CS. Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Ophthalmology 2014;121:358–364.

11. Sukumaran S, Marzan K, Shaham B, Reiff A. High dose infliximab in the treatment of refractory uveitis: does dose matter? ISRN Rheumatol 2012;2012:765380.

12. Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, et al. Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics 2012;6:5–12.

13. El Garf AK, Shahin AA, Shawky SA, Azim MA, Effat DA, Abdelrahman SK. Efficacy of infliximab in refractory posterior uveitis in Behcet’s disease patients. The Egyptian Rheumatologist 2018;40:93–97.

14. Keino H, Okada A, Watanabe T, Taki W. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet’s disease. Eye 2014;28:1100–1106.

15. Fabiani C, Sota J, Vitale A, Emmi G, Vannozzi L, Bacherini D, et al. Ten-year retention rate of infliximab in patients with Behçet’s disease-related uveitis. Ocul Immunol Inflamm 2019;27:34–39.

16. Giardina A, Ferrante A, Ciccia F, Vadalà M, Giardina E, Triolo G. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs. Rheumatol Int 2011;31:33–37.

17. Okada AA, Goto H, Ohno S, Mochizuki M, Ocular Behçet’s Disease Research Group of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol 2012;130:592–598.

18. Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom- Guillaume S, Edelsten C, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis 2018;77:1107–1117.

19. Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol 2005;33:461–468.

20. Miraldi Utz V, Bulas S, Lopper S, Fenchel M, Sa T, Mehta M, et al. Effectiveness of long-term infliximab use and impact of treatment adherence on disease control in refractory, non-infectious pediatric uveitis. Pediatr Rheumatol Online J 2019;17:79.

21. Simonini G, Druce K, Cimaz R, Macfarlane GJ, Jones GT. Current evidence of anti–tumor necrosis factor α treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. Arthritis Care Res 2014;66:1073–1084.

22. Cecchin V, Zannin ME, Ferrari D, Pontikaki I, Miserocchi E, Paroli MP, et al. Long-term safety and efficacy of adalimumab and infliximab for uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2018;45:1167– 1172.

23. Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 2005;43:7–11.

24. Naganuma M, Sakuraba A, Hisamatsu T, Ochiai H, Hasegawa H, Ogata H, et al. Efficacy of infliximab for induction and maintenance of remission in intestinal Behçet’s disease. Inflamm Bowel Dis 2008;14:1259–1264.

25. Sharma PK, Markov GT, Bajwa A, Foster CS. Longterm efficacy of systemic infliximab in recalcitrant retinal vasculitis. Retina 2015;35:2641–2446.

26. Maleki A, Sahawneh HF, Ma L, Meese H, He Y, Foster CS. Infliximab therapy in patients with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy. Retina 2017;37:836–843.

27. Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, et al. Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics 2012;6:5–12.

28. El Garf AK, Shahin AA, Shawky SA, Azim MA, Effat DA, Abdelrahman SK. Efficacy of infliximab in refractory posterior uveitis in Behcet’s disease patients. The Egyptian Rheumatologist 2018;40:93–97.

29. Lee LY, Sanderson JD, Irving PM. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol 2012;24:1078–1085.

30. LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol 2017;13:181–188.

31. Ramanan AV, Dick AD, Jones AP, Hughes DA, McKay A, Rosala-Hallas A, et al. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT. Health Technol Assess 2019;23:1–140.

32. Horton S, Jones AP, Guly CM, Hardwick B, Beresford MW, Lee RW, et al. Adalimumab in juvenile idiopathic arthritis-associated uveitis: 5-year follow-up of the bristol participants of the SYCAMORE trial. Am J Ophthalmol 2019;207:170–174.

33. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012;250:713–720.

34. Rudwaleit M, Rødevand E, Holck P, Vanhoof J, Kron M, Kary S, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis 2009;68:696–701.

35. Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, et al. Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 2017;36:183–189.

36. Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol 2013;97:481–486.

37. Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med 2016;375:932–943.

38. Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, Cordero- Coma M, Ortega G, Ortego N, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 2012;119:1575–1581.

39. Dobner BC, Max R, Becker MD, Heinz C, Veltrup I, Heiligenhaus A, et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol 2013;97:134–138.

40. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016;388:1183–1192.

41. Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology 2018;125:1075–1087.

42. Lejoyeux R, Diwo E, Vallet H, Saadoun D, Tezenas du Montcel S, Bodaghi B, et al. INFLIXIMAB and ADALIMUMAB in uveitic macular edema. Ocul Immunol Inflamm 2018;26:991–996.

43. Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol 2016;68:1522–1530.

44. Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm 2012;20:18–26.

45. Fabiani C, Vitale A, Emmi G, Bitossi A, Lopalco G, Sota J, et al. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clin Rheumatol 2019;38:63–70.

46. Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye 2009;23:1868–1870.

47. Boyce EG, Halilovic J, Stan-Ugbene O. Golimumab: review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor. Clin Ther 2010;32:1681–1703.

48. Calvo-Río V, Blanco R, Santos-Gómez M, Rubio-Romero E, Cordero-Coma M, Gallego-Flores A, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum 2016;46:95– 101.

49. van Bentum RE, Heslinga SC, Nurmohamed MT, Gerards AH, Griep EN, Koehorst CBJM, et al. Reduced occurrence rate of acute anterior uveitis in ankylosing spondylitis treated with golimumab - the GO-EASY study. J Rheumatol 2019;46:153–159.

50. Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Vannozzi L, et al. Rapid and sustained efficacy of golimumab in the treatment of multirefractory uveitis associated with Behçet’s disease. Ocul Immunol Inflamm 2019;27:58–63.

51. Vitale A, Emmi G, Lopalco G, Fabiani C, Gentileschi S, Silvestri E, et al. Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet’s disease. Clin Rheumatol 2017;36:2063–2069.

52. Cordero-Coma M, Calvo-Río V, Adán A, Blanco R, Álvarez- Castro C, Mesquida M, et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators Inflamm 2014;2014:717598.

53. Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm 2014;22:90–95.

54. Rudwaleit M, Rosenbaum JT, Landewé R, Marzo-Ortega H, Sieper J, van der Heijde D, et al. Observed incidence of uveitis following certolizumab pegol treatment in patients with axial spondyloarthritis. Arthritis Care Res 2016;68:838–844.

55. Gómez-Santos M, Llorenz V, Mesquida M, Blanco R, Calvo- Rio V, Maiz O, et al. Efficacy of certolizumab in patient with refractory uveitis to other biologic therapy. Study of 7 cases [? ]. Abstract presented at: 2014 ACR/ARHP Annual Meeting; 2014 Nov 14–19; Boston, MA.

56. Sharon Y, Chu DS. Certolizumab pegol - tumor necrosis factor inhibitor for refractory uveitis. Am J Ophthalmol Case Rep 2020;18:100633.

57. Llorenç V, Mesquida M, Sainz de la Maza M, Blanco R, Calvo V, Maíz O, et al. Certolizumab pegol, a new anti-TNF- α in the armamentarium against ocular inflammation. Ocul Immunol Inflamm 2016;24:167–172.

58. Tosi GM, Sota J, Vitale A, Rigante D, Emmi G, Lopalco G, et al. Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clin Exp Rheumatol 2019;37:680–683.

59. van der Horst-Bruinsma I, van Bentum R, Verbraak FD, Rath T, Rosenbaum JT, Misterska-Skora M, et al. The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW. RMD Open 2020;6:e001161.

60. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003;121:437–440.

61. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248–3252.

62. Iqbal KM, Hay MW, Emami-Naeini P. Medication-induced uveitis: an update. J Ophthalmic Vis Res 2021;16:84–92.

63. Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol 2018;37:2233–2240.

64. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633–652.

65. Fabiani C, Vitale A, Emmi G., Lopalco G, Vannozzi L, Guerriero S, et al. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 2017;36:191–197.

66. Fabiani C, Vitale A, Rigante D, Emmi G, Lopalco G, Di Scala G, et al. The presence of uveitis is associated with a sustained response to the interleukin (IL)-1 inhibitors anakinra and canakinumab in Behçet’s disease. Ocul Immunol Inflamm 2020;28:298–304.

67. Ugurlu S, Ucar D, Seyahi E, Hatemi G, Yurdakul S. Canakinumab in a patient with juvenile Behcet’s syndrome with refractory eye disease. Ann Rheum Dis 2012;71:1589–1591.

68. Lopalco G, Schiraldi S, Venerito V, Guerriero S, Iannone F. Effectiveness and safety profile of anakinra in a HLA-B27 positive patient with multiple sclerosis-associated uveitis. Mult Scler Relat Disord 2020;42:102152.

69. Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, et al. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol 2018;37:2233–2240.

70. Gül A, Tugal-Tutkun I, Dinarello CA, Reznikov L, Esen BA, Mirza A, et al. Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: an open-label pilot study. Ann Rheum Dis 2012;71:563–566.

71. Tugal-Tutkun I, Kadayifcilar S, Khairallah M, Lee SC, Ozdal P, Özyazgan Y, Song JH, et al. Safety and efficacy of gevokizumab in patients with Behçet’s disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm 2017;25:62–70.

72. Tugal-Tutkun I, Pavesio C, De Cordoue A, Bernard- Poenaru O, Gül A. Use of gevokizumab in patients with Behçet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm 2018;26:1023–1033.

73. Knickelbein JE, Tucker WR, Bhatt N, Armbrust K, Valent D, Obiyor D, et al. Gevokizumab in the treatment of autoimmune non-necrotizing anterior scleritis: results of a phase I/II clinical trial. Am J Ophthalmol 2016;172:104–110.

74. Wroblewski K, Sen HN, Yeh S, Faia L, Li Z, Sran P, et al. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease. Can J Ophthalmol 2011;46:322–328.

75. Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See RF, Letko E, et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 2005;112:764–770.

76. Brooks M. MS drug daclizumab (Zinbryta) pulled from the market [Internet]. Medscape; 2018. Available from: https://www.medscape.com/viewarticle/893352

77. Ramanan AV, Dick AD, Guly C, McKay A, Jones AP, Hardwick B, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol 2020;2:e135–e141.

78. Calvo-Río V, Santos-Gómez M, Calvo I, González- Fernández MI, López-Montesinos B, Mesquida M, et al. Anti-Interleukin-6 receptor tocilizumab for severe juvenile idiopathic arthritis-associated uveitis refractory to anti-tumor necrosis factor therapy: a multicenter study of twenty-five patients. Arthritis Rheumatol 2017;69:668– 675.

79. Atienza-Mateo B, Calvo-Río V, Beltrán E, Martínez- Costa L, Valls-Pascual E, Hernández-Garfella M, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet’s disease: multicentre retrospective study. Rheumatology 2018;57:856–864.

80. Adán A, Mesquida M, Llorenç V, Espinosa G, Molins B, Hernández MV, et al. Tocilizumab treatment for refractory uveitis-related cystoid macular edema. Graefes Arch Clin Exp Ophthalmol 2013;251:2627–2632.

81. Deuter CME, Zierhut M, Igney-Oertel A, Xenitidis T, Feidt A, Sobolewska B, et al. Tocilizumab in uveitic macular edema refractory to previous immunomodulatory treatment. Ocul Immunol Inflamm 2017;25:215–220.

82. Mesquida M, Molins B, Llorenç V, Hernández MV, Espinosa G, Sainz de la Maza M, et al. Twenty-four month follow-up of tocilizumab therapy for refractory uveitisrelated macular edema. Retina 2018;38:1361–1370.

83. Vegas-Revenga N, Calvo-Río V, Mesquida M, Adán A, Hernández MV, Beltrán E, et al. Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients. Am J Ophthalmol 2019;200:85–94.

84. Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, et al. Primary (month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol 2017;183:71–80.

85. Heissigerová J, Callanan D, de Smet MD, Srivastava SK, Karkanová M, Garcia-Garcia O, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN Study. Ophthalmology 2019;126:428–437.

86. Fleischmann R, Genovese MC, Lin Y, St John G, van der Heijde D, Wang S, et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up. Rheumatology 2020;59:292–302.

87. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013;120:777–787.

88. Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 2019;21:111.

89. Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol 2015;172:1371–1383.

90. Mugheddu C, Atzori L, Del Piano M, Lappi A, Pau M, Murgia S, et al. Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol Ther 2017;30.

91. Chateau T, Angioi K, Peyrin-Biroulet L. Two cases of successful ustekinumab treatment for non-infectious uveitis associated with Crohn’s disease. J Crohns Colitis 2020;14:571.

92. Lasave AF, You C, Ma L, Abusamra K, Lamba N, Valdes Navarro M, et al. Long-term outcomes of rituximab therapy in patients with noninfectious posterior uveitis refractory to conventional immunosuppressive therapy. Retina 2018;38:395–402.

93. Miserocchi E, Modorati G, Berchicci L, Pontikaki I, Meroni P, Gerloni V. Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis. Br J Ophthalmol 2016;100:782–786.

94. Ahmed A, Foster CS. Cyclophosphamide or rituximab treatment of scleritis and uveitis for patients with granulomatosis with polyangiitis. Ophthalmic Res 2019;61:44–50.

95. Umran RMR, Shukur ZYH. Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease. Mod Rheumatol 2018;28:197–199.

96. Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, et al. Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010;13:246– 252.

97. Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behçet’s disease with rituximab. Mod Rheumatol 2008;18:306–308.

98. Heiligenhaus A, Miserocchi E, Heinz C, Gerloni V, Kotaniemi K. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology 2011;50:1390–1394.

99. Cao JH, Oray M, Cocho L, Foster CS. Rituximab in the treatment of refractory noninfectious scleritis. Am J Ophthalmol 2016;164:22–28.

100. Iaccheri B, Androudi S, Bocci EB, Gerli R, Cagini C, Fiore T. Rituximab treatment for persistent scleritis associated with rheumatoid arthritis. Ocul Immunol Inflamm 2010;18:223– 225.

101. Ahmadi-Simab K, Lamprecht P, Nölle B, Ai M, Gross WL. Successful treatment of refractory anterior scleritis in primary Sjogren’s syndrome with rituximab. Ann Rheum Dis 2005;64:1087–1088.

102. Ahmed A, Foster CS. Cyclophosphamide or rituximab treatment of scleritis and uveitis for patients with granulomatosis with polyangiitis. Ophthalmic Res 2019;61:44–50.

103. Taylor SR, Salama AD, Joshi L, Pusey CD, Lightman SL. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum 2009;60:1540–1547.

104. Joshi L, Lightman SL, Salama AD, Shirodkar AL, Pusey CD, Taylor SR. Rituximab in refractory ophthalmic Wegener’s granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology 2011;118:2498–2503.

105. Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005;89:1542.

106. Onal S, Kazokoglu H, Koc A, Yavuz S. Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener’s granulomatosis. Ocul Immunol Inflamm 2008;16:230– 232.

107. Umran RMR, Shukur ZYH. Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease. Mod Rheumatol 2018;28:197–199.

108. Monferrer-Adsuara C, Remolí-Sargues L, Hernández-Bel L, Gracia-García A, Hernández-Garfella ML, Cervera-Taulet E. Rituximab in the treatment of Susac’s syndrome: report of a case. Eur J Ophthalmol 2021;31:NP48–NP52.

109. Miserocchi E, Modorati G. Rituximab for noninfectious uveitis. Dev Ophthalmol 2012;51:98–109.

110. Tomkins-Netzer O, Taylor SR, Lightman S. Can rituximab induce long-term disease remission in patients with intraocular non-infectious inflammation? Ophthalmologica 2013;230:109–115.

111. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelvemonth results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263–2271.

112. Tappeiner C, Miserocchi E, Bodaghi B, Kotaniemi K, Mackensen F, Gerloni V, et al. Abatacept in the treatment of severe, longstanding, and refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol 2015;42:706–711.

113. Galstian L, Zholobova E. SAT0510 abatacept in the treatment of juvenile idiopathic arthritis associated with uveitis. Ann Rheum Dis 2015;74:845.

114. Zulian F, Balzarin M, Falcini F, Martini G, Alessio M, Cimaz R, et al. Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res 2010;62:821–825.

115. Birolo C, Zannin ME, Arsenyeva S, Cimaz R, Miserocchi E, Dubko M, et al. Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis. J Rheumatol 2016;43:2068–2073.

116. Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res 2014;66:990– 997.

117. Blair HA, Deeks ED. Abatacept: a review in rheumatoid arthritis. Drugs 2017;77:1221–1233.

118. Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007;144:55–61.

119. Eser-Ozturk H, Sullu Y. The results of interferon-alpha treatment in Behçet uveitis. Ocul Immunol Inflamm 2020;28:498–504.

120. Lee JH, Lee CS, Lee SC. Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients. BMC Ophthalmol 2018;18:52.

121. Kötter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Günaydin I, et al. Human recombinant interferon alfa-2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423–431.

122. Guillaume-Czitrom S, Berger C, Pajot C, Bodaghi B, Wechsler B, Kone-Paut I. Efficacy and safety of interferon-α in the treatment of corticodependent uveitis of paediatric Behçet’s disease. Rheumatology 2007;46:1570–1573.

123. Sobaci G, Erdem U, Durukan AH, Erdurman C, Bayer A, Köksal S, et al. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet’s uveitis refractory to conventional treatments. Ophthalmology 2010;117:1430–1435.

124. Bodaghi B, Gendron G, Wechsler B, Terrada C, Cassoux N, Thi Huong DL, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:335–339.

125. Deuter CM, Zierhut M, Möhle A, Vonthein R, Stöbiger N, Kötter I. Long-term remission after cessation of interferon- α treatment in patients with severe uveitis due to Behçet’s disease. Arthritis Rheum 2010;62:2796–2805.

126. De Simone L, Sangiovanni A, Aldigeri R, Mastrofilippo V, Bolletta E, Invernizzi A, et al. Interferon alpha-2a treatment for post-uveitic refractory macular edema. Ocul Immunol Inflamm 2020;28:322–328.

127. Deuter CM, Doycheva D, Koetter I, Zierhut M. Longterm results of treatment with interferon alpha for chronic uveitic cystoid macular edema. Invest Ophthalmol Vis Sci 2012;53:4262.

128. Oray M, Onal S, Uludag G, Akbay AK, Tugal-Tutkun I. Interferon alpha for the treatment of cystoid macular edema associated with presumed ocular tuberculosis. J Ocul Pharmacol Ther 2017;33:304–312.

129. Invernizzi A, Iannaccone F, Marchi S, Mastrofilippo V, Coassin M, Fontana L, et al. Interferon alpha-2a for the treatment of post-infectious uveitis secondary to presumed intraocular tuberculosis. Ocul Immunol Inflamm 2019;27:643–650.

130. Mackensen F, Jakob E, Springer C, Dobner BC, Wiehler U, Weimer P, et al. Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol 201;156:478–486.e1.

131. Sleijfer S, Bannink M, Van Gool AR, Kruit WH, Stoter G. Side effects of interferon-alpha therapy. Pharm World Sci 2005;27:423–431.

132. Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 2018;13:53–55.

133. Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm 2019;27:1232–1234.

134. Miserocchi E, Giuffrè C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritisassociated uveitis. Clin Rheumatol 2020;39:847–851.

135. Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 2019;21:89.

136. Yamanuha J, Albini T. Current and new steroid therapy in noninfectious uveitis. Retina Specialist [Internet]. 2019. Available from: https://www.retinaspecialist. com/article/current-and-new-steroid-therapy-innoninfectious- uveitis/

137. Thorne JE, Sugar EA, Holbrook JT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) trial. Ophthalmology 2019;126:283–295.

138. Lowder C, Belfort R, Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545–553.

139. Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A. Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye 2013;27:65–71.

140. Jaffe GJ, Foster CS, Pavesio CE, Paggiarino DA, Riedel GE. Effect of an injectable fluocinolone acetonide insert on recurrence rates in chronic noninfectious uveitis affecting the posterior segment: twelve-month results. Ophthalmology 2019;126:601–610.

141. Jaffe GJ, Pavesio CE, Study Investigators. Effect of a fluocinolone acetonide insert on recurrence rates in noninfectious intermediate, posterior, or panuveitis: threeyear results. Ophthalmology 2020;127:1395–1404.

142. Multicenter Uveitis Steroid Treatment Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010;149:550–561.e10.

143. Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic antiinflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA 2017;317:1993–2005.

144. Emami-Naeini P, Yiu G. Medical and surgical applications for the suprachoroidal space. Int Ophthalmol Clin 2019;59:195–207.

145. Henry CR, Shah M, Barakat MR, Dayani P, Wang RC, Khurana RN, et al. Suprachoroidal CLS-TA for noninfectious uveitis: an open-label, safety trial (AZALEA). Br J Ophthalmol 2021;bjophthalmol-2020-318019.

146. Yeh S, Khurana RN, Shah M, Henry CR, Wang RC, Kissner JM, et al. Efficacy and safety of suprachoroidal CLS-TA for macular edema secondary to noninfectious uveitis: phase 3 randomized trial. Ophthalmology 2020;127:948–955.

147. Conrady CD, Yeh S. A review of ocular drug delivery platforms and drugs for infectious and noninfectious uveitis: the past, present, and future. Pharmaceutics 2021;13:1224.

148. Taylor SR, Banker A, Schlaen A, Couto C, Matthe E, Joshi L, et al. Intraocular methotrexate can induce extended remission in some patients in noninfectious uveitis. Retina 2013;33:2149–2154.

149. Taylor SR, Habot-Wilner Z, Pacheco P, Lightman SL. Intraocular methotrexate in the treatment of uveitis and uveitic cystoid macular edema. Ophthalmology 2009;116:797–801.

150. Macular Edema Ranibizumab v. Intravitreal Anti- Inflammatory Therapy Trial (MERIT) (2017). Clinicaltrial.gov identifier: NCT02623426. Available from: https: //clinicaltrials.gov/ct2/show/NCT02623426?cond= Macular+Oedema+Ranibizumab+v.+Intravitreal+antiinflammatory+ Therapy+Trial&draw=2&rank=1

151. Frenkel S, Hendler K, Siegal T, Shalom E, Pe’er J. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol 2008;92:383–388.

152. Merrill PT, Clark WL, Banker AS, Fardeau C, Franco P, LeHoang P, et al. Efficacy and safety of intravitreal sirolimus for noninfectious uveitis of the posterior segment: results from the Sirolimus Study Assessing Double-Masked Uveitis Treatment (SAKURA) program. Ophthalmology 2020;127:1405–1415.

153. Vigil EM, Sepah YJ, Watters AL, Sadiq MA, Ansari M, Bittencourt MG, et al. Assessment of changes in quality of life among patients in the SAVE Study – sirolimus as therapeutic approach to uVEitis: a randomized study to assess the safety and bioactivity of intravitreal and subconjunctival injections of sirolimus in patients with noninfectious uveitis. J Ophthalmic Inflamm Infect 2015;5:13.

154. Ibrahim MA, Sepah YJ, Watters A, Bittencourt M, Vigil EM, Do DV, et al. One-year outcomes of the SAVE study: sirolimus as a therapeutic approach for UVEitis. Transl Vis Sci Technol 2015;4:4.

155. Nguyen QD, Sadiq MA, Soliman MK, Agarwal A, Do DV, Sepah YJ. The effect of different dosing schedules of intravitreal sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of non-infectious uveitis (an American ophthalmological society thesis). Trans Am Ophthalmol Soc 2016;114:T3.

156. Hamza MM, Macky TA, Sidky MK, Ragab G, Soliman MM. Intravitreal infliximab in refractory uveitis in Behcet’s disease: a safety and efficacy clinical study. Retina 2016;36:2399–2408.

157. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). Retina 2010;30:71–80.

158. Giansanti F, Ramazzotti M, Vannozzi L, Rapizzi E, Fiore T, Iaccheri B, et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci 2008;49:1151–1156.

159. Theodossiadis PG, Liarakos VS, Sfikakis PP, Charonis A, Agrogiannis G, Kavantzas N, et al. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol 2009;247:273–281.

160. Kheir WJ, Mehanna CJ, Abdul Fattah M, Al Ghadban S, El Sabban M, Mansour AM, et al. Intravitreal adalimumab for the control of breakthrough intraocular inflammation. Ocul Immunol Inflamm 2018;26:1206–1211.

161. Hamam RN, Barikian AW, Antonios RS, Abdulaal MR, Alameddine RM, El Mollayess G, et al. Intravitreal adalimumab in active noninfectious uveitis: a pilot study. Ocul Immunol Inflamm 2016;24:319–326.

162. Sobolewska B, Chee SP, Zaguia F, Goldstein DA, Smith JR, Fend F, et al. Vitreoretinal lymphoma. Cancers 2021;13:3921.

163. Hashida N, Ohguro N, Nishida K. Efficacy and complications of intravitreal rituximab injection for treating primary vitreoretinal lymphoma. Transl Vis Sci Technol 2012;1:1.

164. Eyevensys. Plasmid-based uveitis therapy proceeding to phase I trial [Internet]. San Francisco, CA: American Academy of Ophthalmology; 2017. Available from: https://www.aao.org/headline/plasmid-based-uveitistherapy- proceeding-to-phase-

165. Buggage R, Behar-Cohen FF. EYS606 for the treatment of chronic non-infectious uveitis (NIU): results from part 1 of a first-in-human (EYS606-CT1) study. Invest Ophthalmol Vis Sci 2020;61:3170.

166. Businesswire. Eyevensys presents initial data from phase I/II trial of innovative, non-viral gene therapy for ocular diseases at 11th annual ophthalmology innovation summit [Internet]. Businesswire; 2019. Available from: https://www.businesswire.com/news/ home/20191011005298/en/Eyevensys-Presents-Initial- Data-from-Phase-III-Trial-of-Innovative-Non-Viral- Gene-Therapy-for-Ocular-Diseases-at-11th-Annual- Ophthalmology-Innovation-Summit

167. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 2005;140:509–516.

168. Jabs DA. Immunosuppression for the uveitides. Ophthalmology 2018;125:193–202.